We also found that patients with IDH1/2 mut gliomas and high Ki-67 expression (Group 2) had worse clinical outcome than did patients with DH1/2 wt gliomas and low Ki-67 expression (Group 3). The gene discussed is IDH1; the disease is central nervous system cancer.